BridgeBio Oncology Therapeutics Inc (BBOT) Stock Price & News

Why is BBOT down 3.90%?

Dive Deeper

BBOT:NASDAQ

BridgeBio Oncology Therapeutics Inc

$3.94

-3.90%

(-0.16) 1D

$3.94

0.00% (0.00)

After hours

Closed: Oct 1, 4:00:01 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for BBOT...

Open

$4.05

High

$4.10

Low

$3.82

Mkt. cap

315.89M

Avg. vol.

596.10K

Volume

1.36M

52-wk high

$14.87

52-wk low

$3.79

EPS

-$3.04

Shares outstanding

80.17M

No. of employees

Open

$4.05

High

$4.10

Low

$3.82

Mkt. cap

315.89M

Avg. vol.

596.10K

Volume

1.36M

52-wk high

$14.87

52-wk low

$3.79

EPS

-$3.04

Shares outstanding

80.17M

No. of employees

Related stocks

RLAY

Relay Therapeutics Inc

$18.49

+2.44%

BNAI

Brand Engagement Network Inc

News stories

From web sources and news partners

Barron's

9 minutes ago

Twilio and Vylor Stock Join the S&P 500

TradingView

1 hour ago

S&P 500, Nasdaq, Dow Futures Inch Higher As Investors Cheer Cooling Yields — GOOGL, MU, MAT, NVDA In Focus

富途牛牛

48 minutes ago

The superficial prosperity of U.S. stocks fails to mask underlying weakness! While the S&P 500 is less than 2% away from its historical highs, small-cap stocks, banks, and utilities have suffered sharp declines.

ChartMill

5 hours ago

What's going on in today's session: S&P500 movers

About BridgeBio Oncology Therapeutics Inc

CEO-

Employees88

Founded2016

HeadquartersSouth San Francisco, California, United States

SectorBiotechnology

Websitebbotx.com

Analyst	Recommendation	Action	Price target	Projected	Date
Andrew Berens Leerink Partners	Buy	Reiterated	$25.00	+534.5%	09/18/2026
Priyanka Grover J.P. Morgan	Buy	Reiterated	-	-	09/15/2026
Unknown Analyst Wedbush	Buy	Maintained	$25.00	+534.5%	09/09/2026
Biren Amin Piper Sandler	Buy	Maintained	$21.00	+433%	09/09/2026
Sean McCutcheon Raymond James	Buy	Maintained	$22.00	+458.4%	09/09/2026
Laura Prendergast Stifel Nicolaus	Buy	Maintained	$15.00	+280.7%	09/09/2026
John Newman Canaccord Genuity	Buy	Maintained	$20.00	+407.6%	09/09/2026
Sean Laaman Morgan Stanley	Buy	Reiterated	$18.00	+356.9%	08/17/2026
Unknown Analyst J.P. Morgan	Buy	Reiterated	$25.00	+534.5%	08/14/2026
Mazahir Alimohamed Oppenheimer	Buy	Reiterated	$22.00	+458.4%	08/12/2026
David Nierengarten Wedbush	Buy	Maintained	$25.00	+534.5%	05/13/2026
Matthew Biegler Oppenheimer	Buy	Reiterated	$22.00	+458.4%	05/13/2026
Robert Burns H.C. Wainwright	Buy	Reiterated	$29.00	+636%	05/01/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	35.05M	38.07M	39.80M	49.22M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	14.13M	5.33M	6.38M	10.96M
Operating expense	49.18M	43.41M	46.18M	60.19M
Total operating expenses	49.18M	43.41M	46.18M	60.19M
Operating income	-49.18M	-43.41M	-46.18M	-60.19M
Other non operating income	980.00K	187.00K	129.00K	182.00K
EBT including unusual items	-44.76M	-38.80M	-42.11M	-56.45M
EBT excluding unusual items	-44.76M	-38.80M	-42.11M	-56.45M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-44.76M	-38.80M	-42.11M	-56.45M
Net profit margin	-	-	-	-
Earnings per share	-1.03	-0.49	-0.53	-0.71
Interest and investment income	3.44M	4.42M	3.94M	3.55M
Interest expense	-	-	-	-
Net interest expenses	3.44M	4.42M	3.94M	3.55M
Depreciation and amortization charges	-	-	-	-
EBITDA	-49.11M	-43.32M	-46.10M	-60.11M
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything